Destiny Pharma’s novel antibiotic asset clears safety review
Brighton, UK-based Destiny Pharma has announced a positive interim safety review of its ongoing Phase IIb study of its lead antibiotic asset XF-73.
Destiny Pharma ...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement